MedPath

Niacin

Generic Name
Niacin
Brand Names
Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C6H5NO2
CAS Number
59-67-6
Unique Ingredient Identifier
2679MF687A
Background

Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication

Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.

Associated Conditions
Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
Associated Therapies
Dietary supplementation

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Phase 3
Completed
Conditions
Heart Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Diabetes Mellitus
First Posted Date
1999-10-28
Last Posted Date
2016-07-12
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000539

Harvard Atherosclerosis Reversibility Project (HARP)

Phase 2
Completed
Conditions
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
First Posted Date
1999-10-28
Last Posted Date
2016-03-16
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000461

Familial Atherosclerosis Treatment Study

Phase 3
Completed
Conditions
Coronary Arteriosclerosis
Coronary Disease
Heart Diseases
Myocardial Ischemia
Cardiovascular Diseases
Interventions
Other: Placebo for colestipol
Other: Placebo for lovastatin
First Posted Date
1999-10-28
Last Posted Date
2015-12-03
Lead Sponsor
University of Washington
Target Recruit Count
146
Registration Number
NCT00000512
© Copyright 2025. All Rights Reserved by MedPath